AstraZeneca's Wainua Falls Short in Phase III ATTR-CM Study Despite Positive Subgroup Signal
核心洞察
The Phase III CARDIO-TTRansform trial of Wainua (eplontersen) in ATTR-CM failed to meet its primary composite endpoint of cardiovascular mortality and recurrent CV events.
A predefined subgroup analysis showed nominally significant benefit in patients receiving Wainua as standalone therapy without concomitant stabiliser treatment.
Wainua was generally well tolerated with a safety profile consistent with prior clinical findings; full data will be presented at the European Society of Cardiology Congress.
AstraZeneca and Ionis have announced that the Phase III CARDIO-TTRansform study evaluating Wainua (eplontersen) in adults with transthyretin-mediated amyloid cardiomyopathy (搜索) (ATTR-CM) did not meet its primary efficacy endpoint. The trial assessed the composite outcome of cardiovascular mortality and recurrent cardiovascular clinical events over a period of up to 140 weeks, comparing Wainua plus standard stabiliser therapy against placebo.
Sharon Barr, Executive Vice President of BioPharmaceuticals R&D at AstraZeneca, commented: "Although the trial did not meet its primary objective, we believe the results support greater scientific understanding of treatment approaches for the hundreds of thousands of patients worldwide suffering from this progressive and often fatal condition."
Subgroup Analysis Reveals Divergent Outcomes
A predefined analysis identified a potential benefit among patients treated with Wainua as a standalone therapy, where the number of primary composite cardiovascular events was lower than in the placebo group, producing a nominally significant result. However, no meaningful treatment benefit was observed in participants who were already receiving stabiliser therapy at the time of trial enrolment.
This divergence underscores the growing challenge of demonstrating additional clinical benefit as existing ATTR-CM therapies become more widely established in clinical practice.
Safety and Tolerability
Wainua was generally well tolerated throughout the study, with a safety profile consistent with previous clinical findings. AstraZeneca and Ionis have indicated they will analyse the full dataset to further understand the results and intend to present the complete findings at the upcoming European Society of Cardiology Congress.
Strategic Implications
The outcome represents a setback for AstraZeneca's plans to broaden Wainua's use beyond its current approved indication for hereditary transthyretin-mediated amyloid polyneuropathy (搜索). Despite the disappointing trial result, AstraZeneca continues to be supported by solid business fundamentals, including strong profitability, healthy margins, and attractive returns. The company has maintained its financial guidance while delivering encouraging pipeline progress.
AstraZeneca's Cardiovascular, Renal & Metabolism portfolio targets diseases affecting the heart, kidneys, liver, and pancreas through therapies designed to address their underlying biological mechanisms. The company aims to improve patient outcomes by enabling earlier diagnosis and delivering more effective treatments to millions of people worldwide.